FOX04-DRI 5mg

OVERVIEW

FOX04-DRI (5mg) is one of the reference peptides New Zealand Peptides keeps in stock for laboratory research, alongside our flagship line-up headed by Retatrutide. It is referenced in research protocols for its reproducibility, lyophilised shelf stability, and straightforward reconstitution. Each FOX04-DRI vial is produced in accredited peptide synthesis facilities and independently batch-tested for identity, purity and consistency before it is released for sale. Supplied as a 5mg lyophilised powder, FOX04-DRI sits alongside the rest of our longevity & cellular research peptides range for controlled, in-vitro experimental work.

KEY FEATURES

• High-purity FOX04-DRI research peptide
• 5mg lyophilised powder per vial
• HPLC-MS verified purity (99.79%)
• Produced in accredited laboratories
• Sterile, tamper-evident vial
• Dispatched from New Zealand before the 2pm cut-off

SPECIFICATIONS

Product Name

FOX04-DRI 5mg

Peptide Grade

Research Grade

Quantity

5mg per vial

Form

Lyophilised powder

Purity

99.79% (HPLC-MS tested)

Appearance

White / off-white lyophilised powder

Storage

Cool, dry; refrigerate for long-term stability

Packaging

Sterile, tamper-evident vial

WHY ORDER FROM NEW ZEALAND PEPTIDES

New Zealand Peptides sources and tests every batch we sell, from Retatrutide and Tirzepatide through to the rest of the bench. FOX04-DRI is HPLC-MS verified for identity and purity before release, then dispatched NZ-wide by NZ Post Courier in discreet packaging, with free tracked shipping on orders over $100 NZD. Bulk pricing applies across multi-vial orders and our support team can be reached at support@newzealandpeptides.co.nz.